Carbamazepine Tablet, Extended Release
NDC Package 60290-059-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Carbamazepine tablets is carbamazepine is used to prevent and control seizures. This formulation utilizes a tablet, extended release delivery system. Marketed by Umedica Laboratories Usa Inc., this product is identified by NDC 60290-059 and is authorized under FDA application ANDA216594.

Identification & Billing

NDC Package Code
60290-059-02
Package Description
1000 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
60290-059
11-Digit Billing Format
60290005902
RxNorm Crosswalk
  • RxCUI: 199378 - carBAMazepine 100 MG 12HR Extended Release Oral Tablet
  • RxCUI: 199378 - 12 HR carbamazepine 100 MG Extended Release Oral Tablet
  • RxCUI: 199378 - carbamazepine 100 MG 12 HR Extended Release Oral Tablet
  • RxCUI: 402505 - carBAMazepine 200 MG 12HR Extended Release Oral Tablet
  • RxCUI: 402505 - 12 HR carbamazepine 200 MG Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Carbamazepine
Non-Proprietary Name
Carbamazepine
Substance Name
Carbamazepine
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
CARBAMAZEPINE 200 mg/1
Pharmacologic Class
Usage Information
Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.

Regulatory & Marketing

Labeler Name
Umedica Laboratories Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA216594
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-20-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (60290-059). Click a package code to view its specific billing and regulatory data.

60290-059-01
100 TABLET, EXTENDED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 60290-059-02 identifies a specific commercial package of 1000 tablet, extended release in 1 bottle of Carbamazepine, a human prescription drug labeled by Umedica Laboratories Usa Inc.. This tablet, extended release is formulated for oral use and contains carbamazepine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Umedica Laboratories Usa Inc. on August 20, 2022. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.

How is this Umedica Laboratories Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 60290005902. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
60290-059-02
11-Digit CMS (5-4-2)
60290-0059-02

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.